Paper7031389
A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation.
Shepard CC. Lepr Rev, 1981. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation. Papers, record 7031389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7031389
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leprosy | Major topic |
| Mycobacterium leprae | Major topic |
| Rifampin | Major topic |
| Animals | |
| Clinical Trials as Topic | |
| Drug Evaluation, Preclinical | |
| Humans | |
| Mice | |
| Microbial Sensitivity Tests |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 21430881 | Leprosy therapy, past and present: can we hope to eliminate it? | Indian J Dermatol | 2010 | https://conductscience.org/library/papers/21430881 | PubMed |
| 19596891 | The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19596891 | PubMed |
| 18573938 | Powerful bactericidal activity of moxifloxacin in human leprosy. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18573938 | PubMed |
| 8141581 | Clinical trial of sparfloxacin for lepromatous leprosy. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8141581 | PubMed |
| 8031029 | Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8031029 | PubMed |
| 7979302 | Clinical trial of fusidic acid for lepromatous leprosy. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7979302 | PubMed |
| 7698121 | Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. | Eur J Clin Microbiol Infect Dis | 1994 | https://conductscience.org/library/papers/7698121 | PubMed |
| 3402581 | The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. | Eur J Epidemiol | 1988 | https://conductscience.org/library/papers/3402581 | PubMed |
| 1737148 | A clinical trial of minocycline in lepromatous leprosy. | BMJ | 1992 | https://conductscience.org/library/papers/1737148 | PubMed |
| 1539986 | Novel assay for screening rifamycin B-producing mutants. | Appl Environ Microbiol | 1992 | https://conductscience.org/library/papers/1539986 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7031389
GET https://conductscience.org/api/papers/v1/7031389/authors